SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / Medical3-DIMENSIONAL PHARMACEUTICALS (DDDP)


Previous 10 Next 10 
To: keokalani'nui who wrote (56)1/10/2002 10:09:48 PM
From: Miljenko Zuanic
   of 146
 
<<(now a 3dp shareholder too)>>

Welcome!

Somehow 3DP remained me on VRTX-NBIX combo. Hope they can select only the good part of this combination.

Miljenko

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (57)1/29/2002 6:00:46 AM
From: mopgcw
   of 146
 
3-Dimensional Pharmaceuticals Announces Webcast of Presentation At U.S. Bancorp Piper Jaffray Healthcare Conference

YARDLEY, Pa., Jan. 23 /PRNewswire-FirstCall/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - news) today announced that David C. U'Prichard, Ph.D., Chief Executive Officer, will present at the U.S. Bancorp Piper Jaffray Healthcare Conference at 9:00 a.m. ET on Tuesday, January 29, 2002.

3DP's presentation will be webcast live and archived for 30 days after the conference. For access to the webcast, please visit the ``Investor Relations'' page at: www.3dp.com and click on the ``Events Calendar'' link.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: mopgcw who wrote (58)2/14/2002 9:05:06 PM
From: mopgcw
   of 146
 
3-Dimensional Pharmaceuticals Announces Webcast of Presentation At BIO CEO & Investor Conference

YARDLEY, Pa., Feb. 14 /PRNewswire-FirstCall/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - news) today announced that David C. U'Prichard, Ph.D., Chief Executive Officer, will present at the Fourth Annual BIO CEO & Investor Conference at 10:30 a.m. ET on Friday, February 22, 2002.

3DP's presentation will be webcast live by CCBN and archived for 30 days after the conference. For access to the webcast, please visit the ``Investor Relations'' page at: www.3dp.com and click on the ``Events Calendar'' link.

About the company

3DP (http://www.3dp.com) is an integrated bio-pharmaceuticals company dedicated to revolutionizing small molecule drug discovery and development. 3DP's proprietary platform, DiscoverWorks®, can be applied to virtually any potential drug target. It produces drug candidates suitable for faster development, with fewer resources and a higher probability of success than using conventional drug discovery methods. 3DP is developing its own drug pipeline and collaborates with other pharmaceutical companies in discovery and development.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: mopgcw who wrote (59)2/14/2002 11:52:37 PM
From: Miljenko Zuanic
   of 146
 
Journal of Clinical Oncology, Vol 20, Issue 4 (February), 2002: 1000-1007
© 2002 American Society for Clinical Oncology

Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination
By Nadia Harbeck, Ronald E. Kates, Manfred Schmitt
From the Clinical Research Group, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany.

Address reprint requests to Nadia Harbeck, MD, Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Strasse 22, D-81675 Munich, Germany; email: nadia.harbeck@ lrz.tum.de.

PURPOSE: A strong prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor and plasminogen activator inhibitor type 1 (PAI-1) as individual factors is well established in breast cancer. The improvement in clinical risk assessment gained by combining these factors is evaluated here.

PATIENTS AND METHODS: uPA and PAI-1 levels were prospectively measured by enzyme-linked immunosorbent assay in tumor tissue extracts of 761 patients with primary breast cancer.

RESULTS: In the clinically important subgroup of node-negative patients without adjuvant systemic therapy (n = 269; median follow-up, 60 months), the clinical value of testing both uPA and PAI-1 is demonstrated. The criterion either or both high identifies with high sensitivity the patients at high relapse risk while keeping more than half in the low-risk group. uPA/PAI-1 is the strongest predictor of disease-free survival and overall survival; patients with high uPA/PAI-1 have an increased relapse risk (P < .001; relative risk, 4.8; 95% confidence interval [CI], 2.5 to 9.1), in particular for early relapse. Even within risk groups stratified by established criteria (nodal or menopausal status, tumor size, grade, or steroid hormone receptors), uPA/PAI-1 provides significant risk group discrimination. In the whole collective, the significant interaction between uPA/PAI-1 and adjuvant systemic therapy suggests a benefit from adjuvant therapy in high-risk patients as defined by uPA/PAI-1.

CONCLUSION: The clinical relevance of the two tumor-invasion factors uPA and PAI-1 is greatest when they are used in combination. The particular combination of uPA and PAI-1 (both low v either or both high) is superior to either factor alone and supports risk-adapted individualized therapy decisions.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (60)2/26/2002 10:57:23 AM
From: tuck
   of 146
 
>>SAN CARLOS, Calif. & YARDLEY, Pa.--(BUSINESS WIRE)--Feb. 26, 2002--Inhale Therapeutic Systems, Inc. (Nasdaq:INHL - news) and 3-Dimensional Pharmaceuticals, Inc. (Nasdaq:DDDP - news) today announced a collaborative initiative to use Inhale's proprietary PEGylation technology for 3DP's synthetic thrombopoietin (TPO) mimetic compound (3DP-3534), currently in pre-clinical development for the prevention and treatment of low blood platelet count. Under this agreement, Inhale will supply PEGylation technology, enabling 3DP to synthesize 3DP-3534 which is a PEGylated peptide. 3DP will pay Inhale an upfront fee, milestone payments, manufacturing revenues, and royalties on product sales.

Thrombocytopenia, commonly known as low blood platelet count, is a disease that can prolong blood clotting times, increase the risk of bruising, and, in severe cases, cause internal hemorrhaging. Standard treatment for thrombocytopenia currently is platelet transfusion. About one third of the two million annual procedures in the United States are performed on cancer patients whose platelet count is impaired by chemotherapy, while the remainder are performed on patients with a variety of conditions including HIV/AIDS and hepatitis B and C.

3DP-3534, being developed as a possible therapy to reduce the severity of thrombocytopenia, is a synthetic thrombopoietin (TPO) mimetic that stimulates the human body to increase its production of blood platelets, reducing the need for transfusions. Inhale's PEGylation technology will contribute to the therapeutic potential of 3DP's compound by increasing circulation time in the bloodstream and reducing unwanted recognition by the immune system.

``We are pleased to be collaborating with 3DP to improve the performance and delivery of its TPO mimetic and address a significant medical need. We believe PEGylation potentially could decrease antibody formation and reduce dosing frequency,'' said Ajit Gill, president and chief executive officer of Inhale. ``This collaboration is another validation of the use of PEGylation as the industry standard method for enabling improved performance of macromolecules.''

``Inhale brings leading PEGylation technology and expertise required to develop this product,'' said David U'Prichard, Ph.D., chief executive officer of 3DP. ``3DP is committed to developing oncology therapeutics, and we are initially focusing this program on the development of therapies for thrombocytopenia in cancer patients undergoing certain chemotherapy treatments.''<<

snip

Unclear to me if this is an application of Enzon's PEG technology licensed to INHL. INHL announced three other such deals today, and Enzon promptly announced that two of them used their technology that INHL was sublicensing. This wasn't one of them, so presumably the PEGging for DDDP comes from INHL's Shearwater division.

But Miljenko, what on earth is "manufacturing revenue?"

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (61)2/28/2002 12:19:06 AM
From: mopgcw
   of 146
 
3-Dimensional Pharmaceuticals Announces Financial Results For The Quarter and Year Ended December 31, 2001

YARDLEY, Pa., Feb. 27 /PRNewswire-FirstCall/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - news) today announced results for the fourth quarter and fiscal year ended December 31, 2001. Revenues for the quarter increased to $10.2 million, compared to $3.8 million for the fourth quarter of 2000. Net loss for the quarter was $1.7 million, or $0.08 per share, compared to a net loss of $2.3 million, or $0.11 per share, for the fourth quarter of 2000. For the year ended December 31, 2001, 3DP reported revenues of $28.4 million, compared to $12.4 million for the same period in 2000. Net loss for the year was $11.4 million, or $0.53 per share, compared to $8.2 million, or $0.52 per share, on a pro forma basis for the same period in 2000. (Pro forma loss per common share assumes that all shares of preferred stock, which converted into common stock upon the Company's initial public offering in August 2000, had converted at the original dates of issuance.)

The revenue increases for the quarter result from discovery collaborations and license agreements with Bristol-Myers Squibb and Centocor, Inc. (a wholly owned subsidiary of Johnson & Johnson) that commenced in July 2000 and December 2000, respectively. The revenue increases for the year to date are attributable to the Bristol-Myers Squibb and Centocor agreements as well as a discovery and license agreement with Schering AG, Germany that commenced in May 2000. In addition, included in fourth quarter revenue is a $4.0 million payment resulting from a milestone that the Company achieved in October 2001 in connection with the Centocor, Inc. agreement.

Research and development expenses increased by $4.1 million to $8.7 million for the fourth quarter ended December 31, 2001, compared to $4.6 million for the fourth quarter of 2000. Research and development expenses increased by $15.0 million to $29.6 million for the year ended December 31, 2001, compared to $14.6 million for the year ended December 31, 2000. During 2001, 3DP continued to expand its research and development investments in its internal and collaborative programs. Related to the Company's expansion were increases in personnel and facilities expenses. The Company anticipates that research and development expenses will continue to increase as it advances its research and development programs towards and into human clinical trials. General and administrative expenses increased by $0.9 million to $4.3 million for the quarter ended December 31, 2001 compared to $3.4 million for the fourth quarter of 2000. General and administrative expenses increased by $6.6 million to $15.3 million for the year ended December 31, 2001 compared to $8.7 million for the year ended December 31, 2000. The increases were primarily related to increased management and personnel expenses, increased investments in business development and facilities required to support the Company's continued research and development efforts, and other expenses relating to its operations as a public company.

``The performance of 3DP in 2001 can be described as one of outstanding growth,'' said David C. U'Prichard, Ph.D., Chief Executive Officer of 3DP. ``We nearly doubled the size of our company to 200 people by year-end. We also doubled our research and development expenditures, more than doubled our revenues, and grew by 50 percent the size of our chemistry libraries. Even more exciting was the progress of a number of our key pre-clinical pipeline programs aimed at cancer, rheumatoid arthritis, cardiovascular and pulmonary disease.''

In December 2001, the Company entered into a DiscoverWorks® drug discovery alliance with Johnson & Johnson Pharmaceutical Research & Development and will begin to recognize revenue from this agreement in 2002. For 2002, 3DP's existing collaborations are expected to provide revenues of approximately $24 million relating to up-front fees, research funding payments and license fees. Not included in the 2002 estimate are potential milestone payments from existing agreements or any revenues from new collaborations. Although one of the Company's goals is to enter into additional DiscoverWorks collaborations, 3DP's basic business model is to focus a greater portion of its efforts on internal product research and development. As a result, the Company expects to incur increasing operating losses over the next several years. In connection with the Company's objective to enhance its internal pipeline, in January 2002, 3DP acquired worldwide rights to a pre IND compound from GlaxoSmithKline (GSK) for the prevention and treatment of thrombocytopenia, or low blood platelet count. The Company believes that this compound fits well with its oncology focus. All payments made to GSK will be in 3DP stock. 3DP made an initial payment of 0.5 million shares and may issue up to 1.9 million additional shares should the compound achieve certain key development and regulatory milestone events. With respect to the initial 0.5 million shares issued, the Company expects to recognize a non-cash in-process research and development charge in the first quarter of 2002 of $4.1 million.

At December 31, 2001, 3DP had cash, cash equivalents and marketable securities of $99.3 million. 3DP intends to use the cash that it receives from its collaborations, along with its existing cash, for research and development, the acquisition or licensing of technologies, the expansion of facilities, general corporate and working capital needs, and possible business combinations.

3DP (http://www.3dp.com) is an integrated bio-pharmaceuticals company dedicated to revolutionizing small molecule drug discovery and development. 3DP's proprietary platform, DiscoverWorks®, has the potential to produce drug candidates suitable for faster development, with fewer resources and a higher probability of success than using conventional drug discovery methods. 3DP is developing its own drug pipeline and collaborates with other pharmaceutical companies in discovery and development.

<snip>

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: mopgcw who wrote (62)3/11/2002 4:17:39 AM
From: mopgcw
   of 146
 
Bitoech Growth NV selling out:

SOURCE: Form 144

ISSUER: 3 DIMENSIONAL PHARMACEUTICALS INC
SYMBOL: DDDP

FILER: BIOTECH GROWTH NV
TITLE: Beneficial Owner
BROKER: JP MORGAN
RESTRICTED SHARES TO SELL: 200,000 DATE REGISTERED: 03/04/02
APPROXIMATE DATE OF SALE: 02/22/02

The Form 144 is filed with the Securities and Exchange Commission to
reflect the intention of any holder of restricted stock to sell those
shares. After the 144 is mailed to the S.E.C., the filer is permitted

to sell the shares, or any fraction of them, within 90 days.

Form 144 data provided by: Washington Service (info@washserv.com)

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: mopgcw who wrote (63)3/11/2002 8:36:58 PM
From: Miljenko Zuanic
   of 146
 
Bastard!

[eom]

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (64)3/12/2002 8:38:48 AM
From: dalroi
   of 146
 
Message #64 from Miljenko Zuanic at Mar 11, 2002 8:36 PM

Bastard!
[eom]

nope , thank you for the cheap shares

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: dalroi who wrote (65)3/12/2002 9:17:43 PM
From: Miljenko Zuanic
   of 146
 
<<nope , thank you for the cheap shares >>

They are selling or intend to sell (they own 15.16 % or 3,260,970 shares) into low trading volume. Why? What purpose is to sell 200K when you have 3.26 M?

So, cheap may become cheaper! <grrr>

They are bastards, none the less.

Miljenko

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10